Fipaxalparant
HZNP-HZN-825-302
Phase 2 small_molecule active
Quick answer
Fipaxalparant for Diffuse Cutaneous Systemic Sclerosis is a Phase 2 program (small_molecule) at Elan Pharma International with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Elan Pharma International
- Indication
- Diffuse Cutaneous Systemic Sclerosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active